Caligan Partners LP Acquires 8.5% Stake in Opus Genetics, Inc. (IRD)

On May 15, 2026, Caligan Partners LP and its Managing Partner, David Johnson, filed a Schedule 13G disclosing a new ownership stake in Opus Genetics, Inc. (ticker: IRD). As of the event date on March 31, 2026, the reporting persons beneficially own 6,075,028 shares of common stock, representing 8.5% of the company's outstanding shares. Caligan Partners LP serves as the investment manager for various funds and accounts that hold these shares, while David Johnson exercises shared voting and dispositive power over the position. The filing indicates that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer. This initial disclosure marks a significant entry into the stock, as the previous ownership was reported at 0%. The calculation of the ownership percentage is based on approximately 71.4 million shares outstanding as of late March 2026.